ArticleAging2022
A signature constructed with mitophagy-related genes to predict the prognosis and therapy response for breast cancer.
Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- PANoptosis-related genes in the prognosis and immune landscape of hepatocellular carcinoma.Immunologic research · 2025Article
- A Multi-Omics Analysis of a Mitophagy-Related Signature in Pan-Cancer.International journal of molecular sciences · 2025Article
- Development and verification of a novel risk model related to ubiquitination linked with prognosis and therapeutic response in clear cell renal cell carcinoma.Scientific reports · 2024Article
- Endocrine and cellular physiology and pathology of the insulin-like growth factor acid-labile subunit.Nature reviews. Endocrinology · 2024Review
- Unveiling the role of TGF-β signaling pathway in breast cancer prognosis and immunotherapy.Frontiers in oncology · 2024Article
- Development and validation of an inflammatory response-related signature in triple negative breast cancer for predicting prognosis and immunotherapy.Frontiers in oncology · 2023Article
- Six mitophagy-related hub genes as peripheral blood biomarkers of Alzheimer's disease and their immune cell infiltration correlation.Frontiers in neuroscience · 2023Article
- Establishment and validation of a ubiquitination-related gene signature associated with prognosis in pancreatic duct adenocarcinoma.Frontiers in immunology · 2023Article
- Construction of a neural network diagnostic model for renal fibrosis and investigation of immune infiltration characteristics.Frontiers in immunology · 2023Article
- From past to future: Bibliometric analysis of global research productivity on nomogram (2000-2021).Frontiers in public health · 2022Review
- Based on different immune responses under the glucose metabolizing type of papillary thyroid cancer and the response to anti-PD-1 therapy.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past decades, the incidence and mortality rates of breast cancer (BC) have increased rapidly; however, molecular biomarkers that can reliably detect BC are yet to be discovered. Our study aimed to identify a novel signature that can predict the prognosis of patients with BC. Data from the TCGA-BRCA cohort were analyzed using univariate Cox regression analysis, and least absolute shrinkage and selection operator (LASSO) analysis was performed to build a stable prognostic model. Subsequently, Kaplan-Meier (K-M) and receiver operating characteristic (ROC) analyses were performed to demonstrate the predictive power of our gene signature. Each patient was assigned to either a low- or high-risk group. Patients with high-risk BC had poorer survival than those with low-risk BC. Cox regression analysis suggested that our signature was an independent prognostic factor. Additionally, decision curve analysis and calibration accurately predicted the capacity of our nomogram. Thus, based on the differentially expressed genes (DEGs) of mitophagy-related tumor classification, we established a 13-gene signature and robust nomogram for predicting BC prognosis, which can be beneficial for the diagnosis and treatment of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.